• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

过氧化物酶体增殖剂萘酚平辅酶A酯在大鼠肝脏胞液中的可饱和结合位点。

Saturable binding sites for the coenzyme A ester of nafenopin, a peroxisome proliferator, in rat liver cytosol.

作者信息

Morgan C, Bronfman M

机构信息

Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.

出版信息

Xenobiotica. 1995 Dec;25(12):1293-300. doi: 10.3109/00498259509061918.

DOI:10.3109/00498259509061918
PMID:8719905
Abstract
  1. At least three different molecular weight binding sites exist in rat liver cytosol for nafenopin-CoA, the coenzyme A ester and metabolic product of the carcinogenic peroxisome proliferator nafenopin. No binding sites for the free drug were observed. 2. Polypeptides of 35-40 kDa molecular weight range where no acyl-CoA binding proteins have been previously described bind the highest proportion of nafenopin-CoA (60-70%). Binding is displaceable by the CoA esters of other peroxisome proliferators (ciprofibrate and tibric acid) and also by oleoyl-CoA but by palmitoyl-CoA. Direct binding studies show that 35-40-kDa polypeptides bind oleoyl-CoA but not oleic or palmitic acid, or palmitoyl-CoA. 3. Polypeptides of 10-14 and 65-70 kDa also bind nafenopin-CoA. However, in contrast with 35-40-kDa polypeptides they also bind oleic and palmitic acid as well as their correspondent acyl-CoA thioesters.
摘要
  1. 大鼠肝脏胞质溶胶中存在至少三种不同分子量的非诺贝特 - 辅酶A结合位点,非诺贝特 - 辅酶A是致癌性过氧化物酶体增殖剂非诺贝特的辅酶A酯和代谢产物。未观察到游离药物的结合位点。2. 分子量范围在35 - 40 kDa的多肽此前未发现有酰基辅酶A结合蛋白,但其结合非诺贝特 - 辅酶A的比例最高(60 - 70%)。其他过氧化物酶体增殖剂的辅酶A酯(环丙贝特和氯贝酸)以及油酰辅酶A可取代这种结合,但棕榈酰辅酶A不能。直接结合研究表明,35 - 40 kDa的多肽结合油酰辅酶A,但不结合油酸或棕榈酸,也不结合棕榈酰辅酶A。3. 10 - 14 kDa和65 - 70 kDa的多肽也结合非诺贝特 - 辅酶A。然而,与35 - 40 kDa的多肽不同,它们还结合油酸和棕榈酸以及它们相应的酰基辅酶A硫酯。

相似文献

1
Saturable binding sites for the coenzyme A ester of nafenopin, a peroxisome proliferator, in rat liver cytosol.过氧化物酶体增殖剂萘酚平辅酶A酯在大鼠肝脏胞液中的可饱和结合位点。
Xenobiotica. 1995 Dec;25(12):1293-300. doi: 10.3109/00498259509061918.
2
Hypolipidaemic drugs are activated to acyl-CoA esters in isolated rat hepatocytes. Detection of drug activation by human liver homogenates and by human platelets.降血脂药物在分离的大鼠肝细胞中被激活为酰基辅酶A酯。用人肝匀浆和人血小板检测药物激活情况。
Biochem J. 1992 May 15;284 ( Pt 1)(Pt 1):289-95. doi: 10.1042/bj2840289.
3
In vitro evidence for involvement of CoA thioesters in peroxisome proliferation and hypolipidaemia.辅酶A硫酯参与过氧化物酶体增殖和低脂血症的体外证据。
Biochim Biophys Acta. 1994 Jan 13;1220(2):118-24. doi: 10.1016/0167-4889(94)90126-0.
4
Xenobiotic acyl-CoA formation: evidence of kinetically distinct hepatic microsomal long-chain fatty acid and nafenopin-CoA ligases.异生素酰基辅酶A的形成:肝微粒体中动力学上不同的长链脂肪酸和萘酚平辅酶A连接酶的证据。
Chem Biol Interact. 1994 Mar;90(3):215-23. doi: 10.1016/0009-2797(94)90011-6.
5
Lack of evidence for a hepatic peroxisome proliferator receptor and an explanation for the binding of hypolipidaemic drugs to liver homogenates.缺乏肝脏过氧化物酶体增殖物激活受体的证据以及降血脂药物与肝脏匀浆结合的解释。
Biochem Pharmacol. 1988 Mar 1;37(5):793-8. doi: 10.1016/0006-2952(88)90163-3.
6
Activation of hypolipidaemic drugs to acyl-coenzyme A thioesters.降血脂药物转化为酰基辅酶A硫酯的激活过程。
Biochem J. 1986 Nov 1;239(3):781-4. doi: 10.1042/bj2390781.
7
Potent peroxisome proliferators inhibit beta-oxidation in the isolated perfused rat liver.强效过氧化物酶体增殖剂可抑制离体灌注大鼠肝脏中的β氧化。
Toxicol Appl Pharmacol. 1996 Oct;140(2):322-7. doi: 10.1006/taap.1996.0227.
8
Detection of a nafenopin-binding protein in rat liver cytosol associated with the induction of peroxisome proliferation by hypolipidemic compounds.在大鼠肝脏胞质溶胶中检测到一种与降血脂化合物诱导过氧化物酶体增殖相关的萘酚平结合蛋白。
Biochem Biophys Res Commun. 1983 Oct 31;116(2):388-93. doi: 10.1016/0006-291x(83)90534-x.
9
In vitro covalent binding of nafenopin-CoA to human liver proteins.萘酚平辅酶A与人肝蛋白的体外共价结合。
Toxicol Appl Pharmacol. 2000 Mar 1;163(2):176-82. doi: 10.1006/taap.1999.8868.
10
The hypolipidemic drug metabolites nafenopin-CoA and ciprofibroyl-CoA are competitive P2Y1 receptor antagonists.
FEBS Lett. 2003 Feb 11;536(1-3):145-50. doi: 10.1016/s0014-5793(03)00044-9.